According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will ...

Whittier Trust Co. increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 2.5% during the third quarter, according to its most recent Form 13F filing with the Securities and ...

Oral semaglutide is currently approved under the brand name Rybelsus ® as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on these findings, ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Novo Nordisk NVO shares have lost 4.5% in the past month compared with the industry’s decline of 1.5%. The company has also ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...

Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.

The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...